Education
About Us
Working with TipRanks
Follow Us
Astellas Pharma Inc (ALPMF)
OTHER OTC:ALPMF
Total Valuation
Astellas Pharma has a market cap or net worth of $26.52B. The enterprise value is $4.68T.
Market Cap$26.52B
Enterprise Value$4.68T
Share Statistics
Astellas Pharma has 1,809,663,100 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding1,809,663,100
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Astellas Pharma’s return on equity (ROE) is 0.03 and return on invested capital (ROIC) is 9.98%.
Return on Equity (ROE)0.03
Return on Assets (ROA)0.02
Return on Invested Capital (ROIC)9.98%
Return on Capital Employed (ROCE)0.11
Revenue Per Employee129.61M
Profits Per Employee3.44M
Employee Count14,754
Asset Turnover0.57
Inventory Turnover1.17
Valuation Ratios
The current PE Ratio of Astellas Pharma is 9.3. Astellas Pharma’s PEG ratio is 0.26.
PE Ratio9.3
PS Ratio1.35
PB Ratio1.71
Price to Fair Value1.71
Price to FCF15.73
Price to Operating Cash Flow―
PEG Ratio0.26
Income Statement
In the last 12 months, Astellas Pharma had revenue of 1.91T and earned 50.75B in profits. Earnings per share was 28.35.
Revenue1.91T
Gross Profit1.56T
Operating Income255.67B
Pretax Income31.24B
Net Income50.75B
EBITDA462.67B
Earnings Per Share (EPS)28.35
Cash Flow
In the last 12 months, operating cash flow was 201.61B and capital expenditures -37.00B, giving a free cash flow of 164.61B billion.
Operating Cash Flow201.61B
Free Cash Flow164.61B
Free Cash Flow per Share90.96
Dividends & Yields
Astellas Pharma pays an annual dividend of $0.247, resulting in a dividend yield of 3.75%
Dividend Per Share$0.247
Dividend Yield3.75%
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.16
52-Week Price Change70.80%
50-Day Moving Average14.86
200-Day Moving Average11.85
Relative Strength Index (RSI)54.60
Average Volume (3m)2.94K
Important Dates
Astellas Pharma upcoming earnings date is Apr 23, 2026, TBA (Confirmed).
Last Earnings DateFeb 4, 2026
Next Earnings DateApr 23, 2026
Ex-Dividend Date―
Financial Position
Astellas Pharma as a current ratio of 1.13, with Debt / Equity ratio of ―
Current Ratio1.13
Quick Ratio0.85
Debt to Market Cap0.33
Net Debt to EBITDA1.62
Interest Coverage Ratio14.46
Taxes
In the past 12 months, Astellas Pharma has paid -19.51B in taxes.
Income Tax-19.51B
Effective Tax Rate-0.62
Enterprise Valuation
Astellas Pharma EV to EBITDA ratio is 7.22, with an EV/FCF ratio of 20.28.
EV to Sales1.75
EV to EBITDA7.22
EV to Free Cash Flow20.28
EV to Operating Cash Flow16.56
Balance Sheet
Astellas Pharma has $188.37B in cash and marketable securities with $725.27B in debt, giving a net cash position of -$748.71B billion.
Cash & Marketable Securities$188.37B
Total Debt$725.27B
Net Cash-$748.71B
Net Cash Per Share-$413.73
Tangible Book Value Per Share-$14.34
Margins
Gross margin is ―, with operating margin of 13.37%, and net profit margin of 2.65%.
Gross Margin―
Operating Margin13.37%
Pretax Margin1.63%
Net Profit Margin2.65%
EBITDA Margin24.19%
EBIT Margin13.78%
Analyst Forecast
The average price target for Astellas Pharma is $14.09, which is 11.43% higher than the current price. The consensus rating is Hold
Price Target$14.09
Price Target Upside1.00% Upside
Analyst ConsensusHold
Analyst Count9
Revenue Growth Forecast―
EPS Growth Forecast―